Globe on Big Pharma R&D Failure
3 Comments
Law Bytes
Episode 79: David Kaye on the Challenges of Reconciling Freedom of Expression and the Regulation of Online Harms
February 1, 2021
Search Results placeholder
Recent Posts
The Law Bytes Podcast, Episode 79: David Kaye on the Challenges of Reconciling Freedom of Expression and the Regulation of Online Harms 
Misplaced Priorities: Why Has Canada’s Privacy Bill Disappeared from the Government’s Legislative Agenda? 
Is Bill C-10 Unconstitutional? A Former Justice Senior General Counsel Makes the Case It Is 
The Law Bytes Podcast, Episode 78: Jennifer Jenkins on What Copyright Term Extension Could Mean for Canada 
The Law Bytes Podcast, Episode 77: The Complexity of Internet Content Regulation – A Conversation with CIPPIC’s Vivek Krishnamurthy
So, repeal C-22
If the drug companies can renege, then so can the goodies that were given to them be taken away.
Seems pretty straightforward to me.
Why aren’t there such things as charitable venture capital orgs? After-all many charities (eg JDRC) contribute to for-profit orgs. It seems to me that charitable donations would go much further if the beneficiaries of donations (R&D orgs) had to contribute returns back to charities. The role of charities like JDRC then would be to encourage R&D firms to take greater risks.
Hey, Michael! Don’t be so ungrateful or narrow minded. What about the bevy of busy lawyers who make gazillions every year doing “research” on their endless litany of pharmaceutical patent cases in the courts? What about all that useful literature and education directed at the medical profession, so that they are better informed about what pills their patients should pop? That takes a lot of “research and development”. And what about all the consumer focus group “research†that goes into those cute Cialis TV commercials?